EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long-Term Cardiovascular Outcomes of Immune Checkpoint Inhibitor-Related Myocarditis: A Large Single-Centre Analysis

Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh-Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler und 1 weitere

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Lorenzo Braghieri und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Myocarditis, Immune Checkpoint Inhibitors, Registries. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI-related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI-related adverse events. Additionally, whether incident irM portends worse long-term CV outcomes remains unclear. We aimed to determine the incidence of long-term CV comorbidities and CV mortality among irM patients. Patients and methods The ICI-related adverse event (irAE) registry was queried to identify irM patients by using Bonaca criteria. Random controls were selected after excluding patients with other concomitant irAEs. Patients' demographics, comorbidities and myocarditis presenting features were gathered. Outcomes included 2-year freedom from CV comorbidities (composite of atrial fibrillation, stroke, myocardial infarction and heart failure) and freedom from CV death. IrM was treated as a time-varying covariate.

Results

Seventy-six patients developed irM at a median of 167 days (mean age 69, 63.2% male, 47% lung cancer). Majority of patients had new wall motion abnormalities or EKG changes on presentation. Mean LVEF was 43%, median peak TnT was 0.81, and median NTproBNP was 2057 at irM onset. Two-year freedom from CV comorbidities (67% vs 86.8%, P < 0.001) and death (93.4% vs 99.3%, P = 0.003) was lower among irM patients. Incident irM was an independent predictor of CV death (HR 8.28, P = 0.048), but not CV comorbidities (HR 2.21, P = 0.080).

Conclusions

This is the largest case–control study on irM highlighting worse long-term CV outcomes. Future studies are needed to establish appropriate therapeutic strategies and efficient screening strategies for irM survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisImmune Checkpoint InhibitorsRegistriesHumansMaleFemaleAgedRetrospective StudiesFollow-Up StudiesIncidenceMiddle AgedTime FactorsSurvival Rate

Stichwörter der Autor:innen

Cardio‐oncologyICI‐related myocarditisImmune‐checkpoint inhibitor

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Department of Internal Medicine, WashU/Barnes-Jewish Hospital, St. Louis, Missouri, USA.
  • Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.
  • Department of Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
  • Department of Rheumatologic and Immunologic Disease, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

ORCID-Profile: Rohit Moudgil

Zitieren

APA

Braghieri, L., Gharaibeh, A., Nkashama, L., Abushouk, A., Abushawer, O., Mehdizadeh-Shrifi, A., Honnekeri, B., Calabrese, C., Menon, V., Funchain, P., Collier, P., Sadler, D., & Moudgil, R. (2025). Long-Term Cardiovascular Outcomes of Immune Checkpoint Inhibitor-Related Myocarditis: A Large Single-Centre Analysis. ESC Heart Failure. https://doi.org/10.1002/ehf2.15131

Vancouver

Braghieri L, Gharaibeh A, Nkashama L, Abushouk A, Abushawer O, Mehdizadeh-Shrifi A, et al. Long-Term Cardiovascular Outcomes of Immune Checkpoint Inhibitor-Related Myocarditis: A Large Single-Centre Analysis. ESC Heart Failure. 2025. doi:10.1002/ehf2.15131

BibTeX
@article{Braghieri2025,
  author = {Braghieri, Lorenzo and Gharaibeh, Ahmad and Nkashama, Lubika and Abushouk, Abdelrahman and Abushawer, Osama and Mehdizadeh-Shrifi, Amir and Honnekeri, Bianca and Calabrese, Cassandra and Menon, Venu and Funchain, Pauline and Collier, Patrick and Sadler, Diego and Moudgil, Rohit},
  title = {Long-Term Cardiovascular Outcomes of Immune Checkpoint Inhibitor-Related Myocarditis: A Large Single-Centre Analysis},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15131}
}
Kostenlos starten →